Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer

Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not known whether receiving either radiation therapy, chemotherapy, or observation is more effective for cancer of the bladder.
  PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy, chemotherapy, or observation following tumor surgery in treating patients who have bladder cancer.

Detailed description: OBJECTIVES:
  -  Compare the efficacy of adjuvant radical radiotherapy vs intravesical BCG or mitomycin vs observation alone after endoscopic resection in terms of the progression rate and survival of patients with stage I, grade 3 transitional cell carcinoma of the bladder.
  -  Determine the toxicity of radical radiotherapy in these patients.
  -  Determine the incidence of carcinoma in situ elsewhere in the bladder and its correlation with the subsequent clinical outcome of these patients.
  OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center, extent of tumor (single tumor without carcinoma in situ (CIS) vs multiple tumors or CIS), and WHO performance status. Patients with a single tumor and no CIS are randomized to arm I or II. Patients with multiple tumors or CIS are randomized to arm II or III.
  -  Arm I: Patients undergo observation only.
  -  Arm II: Patients undergo radical radiotherapy 5 days a week for 6 weeks. Patients found to be node positive on CT scan may undergo pelvic irradiation and remain on study.
  -  Arm III: Patients receive intravesical BCG or mitomycin (at the discretion of the physician) weekly for 6-12 weeks.
  Patients on arms I and III are followed at 3 months after randomization. All patients are followed at 6, 9, and 12 months and then annually thereafter.
  PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.

Eligibility: DISEASE CHARACTERISTICS:
  -  Diagnosis of transitional cell carcinoma of the bladder
  -  Stage T1 Nx M0, grade 3 disease
  -  No muscle invasion at base of tumor
  -  Diagnosis of this stage made within the past 6 months
  -  Earlier diagnosis of tumors with lower stage or grade allowed
  -  No history of higher stage urothelial tumors
  -  Presence of partial involvement of bladder with carcinoma in situ (CIS) or asymptomatic widespread CIS allowed
  -  No widespread CIS causing severe symptoms
  -  Prior complete transurethral resection of tumor with deep biopsy of underlying bladder wall required
  -  Disease currently amenable to adjuvant radiotherapy, followed by cystoscopy with biopsies
  PATIENT CHARACTERISTICS:
  Age:
  -  Any age
  Performance status:
  -  WHO 0-2
  Life expectancy:
  -  Not specified
  Hematopoietic:
  -  Not specified
  Hepatic:
  -  Not specified
  Renal:
  -  Not specified
  Other:
  -  No other prior or concurrent malignancy except nonmelanomatous skin cancer or cervical intraepithelial neoplasia
  PRIOR CONCURRENT THERAPY:
  Biologic therapy:
  -  No more than 1 prior adjuvant treatment with intravesical BCG
  Chemotherapy:
  -  No more than 1 prior adjuvant treatment with intravesical chemotherapy
  Endocrine therapy:
  -  Not specified
  Radiotherapy:
  -  See Disease Characteristics
  Surgery:
  -  See Disease Characteristics
  -  Diathermic removal of associated small papillary growths allowed

Relevance to patient case: not relevant